NovaScan, a clinical-stage oncology company based in Chicago and Milwaukee, recently had its publication titled “The Cole Relaxation Frequency as a Parameter to Identify Cancer in Lung Tissue: Preliminary Animal and ex vivo Patient Studies” accepted in the highly regarded peer-reviewed journal, JMIR Biomedical Engineering.
During this study, NovaScan demonstrated that the Cole Relaxation Frequency correlates strongly with the presence of cancer in lung tissue and in lymph nodes. NovaScan also demonstrated that the Cole frequency can be detected in lung tumors under perfusion, and under simulated breathing. Finally, NovaScan demonstrated that the Cole frequency can be measured when the electrodes are far away from the impedance bridge, opening up possibilities in minimally invasive surgery.
“We are encouraged by the results we’ve obtained. We’ve clearly demonstrated that the Cole frequency can be used to inform on the presence of cancer. We’ve also shown that such measurement isn’t impacted by blood flow or breathing, and we’ve developed significant IP in the process. The clinical potential here is tremendous.” remarked Les Bogdanowicz, NovaScan’s CTO and the lead author of this publication.
NovaScan CEO Craig Davis added “I’m thrilled with the results of this initiative and am delighted to work with such a talented team. We see applications in lung biopsies and in dosing therapeutics directly into active tumors. We see applications in robotics, in thoracic procedures and even beyond. Our technology should substantially improve biopsy diagnostic yield.”
The study was completed at Aurora St Luke’s, the flagship hospital of the Advocate Aurora System, and the Principal Investigator was Dr David Demos.